Free Trial
NYSE:DVA

DaVita Q3 2025 Earnings Report

DaVita logo
$126.35 -0.27 (-0.22%)
As of 12:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DaVita EPS Results

Actual EPS
N/A
Consensus EPS
$3.29
Beat/Miss
N/A
One Year Ago EPS
N/A

DaVita Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.43 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

DaVita Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Wednesday, October 29, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

DaVita Earnings Headlines

DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call
2 Nobel Prize winners warn of once-in-a-generation wealth shift…
An unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.tc pixel
DaVita (NYSE:DVA) Downgraded to "Hold" Rating by Wall Street Zen
Barclays Sticks to Their Hold Rating for DaVita (DVA)
See More DaVita Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DaVita? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DaVita and other key companies, straight to your email.

About DaVita

DaVita (NYSE:DVA) (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions. The company’s growth has broadened its footprint across the United States and into select international markets, enabling it to serve a diverse patient population. DaVita leverages clinical protocols, integrated care teams and telehealth capabilities to enhance treatment consistency and improve health outcomes.

DaVita places a strong emphasis on clinical quality and patient-centered care, operating under stringent regulatory standards and collaborating closely with physicians, hospitals and payers. The company has introduced various initiatives aimed at reducing hospitalization rates, managing complications and promoting patient independence through home therapies. Its data-driven approach supports continuous improvement in care delivery and resource utilization across its network of facilities.

The company’s leadership team is headed by President and Chief Executive Officer Javier Rodriguez, who oversees DaVita’s strategic direction and operational execution. Under his guidance, DaVita continues to pursue innovations in kidney care, digital health and value-based care models, with the goal of advancing treatment accessibility and driving long-term sustainability in the renal healthcare market.

View DaVita Profile

More Earnings Resources from MarketBeat